Business
Sernova to Present Clinical Validation of the Cell Pouch as a Viable, Safe Site for Diabetes Cell Therapy at the American Diabetes Association's Virtual 80th Scientific Sessions
(via TheNewswire) LONDON, ONTARIO - TheNewswire - June 3, 2020 - Serno...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova to Present Clinical Validation of the Cell Pouch as a Viable, Safe Site for Diabetes Cell Therapy at the American Diabetes Association's Virtual 80th Scientific Sessions(via TheNewswire)\n \n \nLONDON, ONTARIO - TheNewswire - June 3, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, is pleased to announce that its submitted abstract entitled \"Clinical Validation of the Implanted Pre-Vascularized Cell Pouch as a Viable, Safe Site for Diabetes Cell Therapy\" has been selected for presentation at the upcoming American Diabetes Association's (ADA) Virtual 80th Scientific Sessions to be held June 12-16, 2020. Sernova's presentation (ePoster 205-LB) will be available to conference attendees beginning June 13, 2020, at 11:00 am EDT.\n\n\n \n\"We are pleased to have the opportunity to present these scientific results at the ADA's Virtual 80th Scientific Sessions,\" said Dr. Philip Toleikis, President and CEO of Sernova. \n\n\n \nAll information contained in the submitted abstract should be considered preliminary and subject to change until the study is fully presented at the 80th Scientific Sessions. All information is subject to embargo until June 13, 2020, at 11:00 am EDT.\n\n\n \nABOUT SERNOVA'S CLINICAL TRIAL\n\n\n \nSernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial at the University of Chicago to assess the safety and tolerability of islet transplantation into the company's patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Patients enrolled in Sernova's clinical trial are incapable of producing c-peptide, a biomarker for insulin produced by islet cells.\n\n\n \nEligible subjects are implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, are transplanted into the Cell Pouch.\n\n\n \nA sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made with regard to the transplant of a second islet dose with ...